Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

scPharmaceuticals Inc. SCPH NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
+129.3%

scPharmaceuticals Inc. (SCPH) is a Biotechnology company in the Healthcare sector, currently trading at $5.67. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SCPH = $13 (+129.3% upside).

Financials: revenue is $36M, +167.3%/yr average growth. Net income is $85M (loss), growing at -41.5%/yr. Net profit margin is -234.4% (negative). Gross margin is 68.7% (-3.3 pp trend).

Balance sheet: total debt is $53M against $13M equity (Debt-to-Equity (D/E) ratio 3.96, leveraged). Current ratio is 7.12 (strong liquidity). Debt-to-assets is 49%. Total assets: $108M.

Analyst outlook: 5 / 8 analysts rate SCPH as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 41/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).

$13.00
▲ 129.28% Upside
Average Price Target
The 12-month price target for scPharmaceuticals Inc. is $13.00.

SCPH SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SCPH

✓
VALUE Pass
100/100
SCPH trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $13, implying +129.3% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
SCPH: +167.3%/yr revenue is, -41.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet SCPH: Debt-to-Equity (D/E) ratio 3.96 (leveraged), Current ratio is 7.12 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
SCPH: Gross margin is 68.7% (-3.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 5 / 8 analysts rate SCPH as buy (63%). Analyst consensus target is $13 (+129.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
SCPH: Net profit margin is -234.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.94-6.28
Volume10.9M
Avg Volume (30D)1.45M
Market Cap$302.2M
Beta (1Y)0.30
Share Statistics
EPS (TTM)-1.91
Shares Outstanding$44.52M
IPO Date2017-11-17
Employees162
CEOJohn H. Tucker
Financial Highlights & Ratios
Revenue (TTM)$36.33M
Gross Profit$24.97M
EBITDA$-77.43M
Net Income$-85.15M
Operating Income$-64.78M
Total Cash$75.66M
Total Debt$52.69M
Net Debt$-22.96M
Total Assets$107.52M
Price / Earnings (P/E)-3
Price / Sales (P/S)8.32
Analyst Forecast
1Y Price Target$13.00
Target High$13.00
Target Low$13.00
Upside+129.3%
Rating ConsensusBuy
Analysts Covering8
Buy 63% Hold 38% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS8106481059

Price Chart

Track all markets on TradingView
SCPH
scPharmaceuticals Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.94 52WK RANGE 6.28

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.92
+3.28%
 DMAC
DMAC
DiaMedica Therapeutics Inc.
$6.54
+3.81%
 MIST
MIST
Milestone Pharmaceuticals Inc.
$2.03
+1.50%
 ONCY
ONCY
Oncolytics Biotech Inc.
$1.02
-2.86%
 MCRB
MCRB
Seres Therapeutics, Inc.
$8.61
+0.35%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message